Teledyne Technologies Inc. (NYSE: TDY) and Varex Imaging Corp. (NASDAQ: VREX) announced on Monday, August 10, 2026, that Teledyne has agreed to acquire Varex in an all-cash transaction valued at approximately $1.1Bn. Varex shareholders would receive $18.90 per share in cash, without interest, and the aggregate figure disclosed by the parties expressly includes Varex equity awards and net debt as of April 3, 2026. Both boards approved the transaction unanimously, and closing is expected in early 2027.

The transaction is component-level consolidation rather than a move into finished medical devices. Varex supplies X-ray tubes, digital detectors, high-voltage interconnects and imaging software to original equipment manufacturers; it does not sell completed imaging systems. Teledyne is acquiring a supplier to the imaging industry rather than a competitor within it, which likely bears on both the strategic case and the antitrust review.

Transaction Overview

Detect Merger Sub, Inc. would merge into Varex, which would become a wholly owned Teledyne subsidiary. The parties disclosed only the aggregate transaction value of approximately $1.1Bn; equity and enterprise value were not separately reported. Varex’s unaffected close on Friday, August 7, 2026 was $12.41, which implies approximately a 52% premium. VREX closed at $18.46 on August 10, up roughly 49%, on 13.2MM shares against 231,000 in the prior session; no volume-weighted average premium was disclosed.

The merger agreement carries a customary no-shop with a fiduciary out subject to matching rights, and Varex would owe a termination fee of $25.3MM on a superior proposal or an adverse recommendation change. Closing requires Varex stockholder approval by a majority of outstanding shares, expiration or termination of the U.S. HSR Act waiting period, clearance under applicable foreign merger control laws and other customary conditions. Varex is required to file a preliminary proxy statement within 30 days of signing, and the outside date is May 10, 2027, extendable to August 10, 2027 in specified circumstances. The transaction is not subject to any financing condition.

Strategic Rationale

Teledyne’s stated rationale rests on complementarity rather than overlap. Executive Chairman Robert Mehrabian noted that the company entered healthcare with the DALSA acquisition in 2011 and said that “while Teledyne and Varex serve similar customers with related technologies, our products are uniquely complementary with minimal overlap.” He observed that Teledyne makes X-ray detectors but not detectors for high-radiation environments such as oncology and that it has never manufactured X-ray tubes. Varex CEO Sunny Sanyal said the transaction “provides a substantial premium for our shareholders and exciting opportunities for our customers and employees.”

The margin differential is likely the clearest financial argument. Varex reported a non-GAAP operating margin of approximately 12% in its most recent quarter, while Teledyne’s Digital Imaging segment ran at 23.4% in the quarter ended June 28, 2026. Neither company disclosed a synergy target, accretion guidance or an EPS impact, so the size and timing of any convergence remain unquantified. Teledyne’s record with DALSA in 2011, e2v in 2017, FLIR Systems at approximately $8.2Bn in May 2021 and select Excelitas businesses at approximately $710MM in February 2025 suggests a repeatable approach.

Teledyne entered the transaction with unusual balance-sheet flexibility, and Varex is its largest acquisition since FLIR. Second quarter 2026 sales were a record $1,662.5MM, up 9.8%, with Digital Imaging at $868.7MM, up 12.7%. Non-GAAP EPS was $6.28, up 20.8%. Net debt was $1,686.9MM, for leverage of 1.1x that management described as the lowest in six years. On the July 22, 2026 earnings call, three weeks before signing, management cited $1.2Bn of undrawn credit facilities and said it was looking at acquisitions “both small and what we call midrange, which would be of the order of $1 billion or more.”

Technology and Competitive Positioning

Varex’s position would probably be difficult to replicate organically. The company supplies X-ray tubes and sources, digital detectors including photon-counting detectors, high-voltage interconnects and imaging software, sold largely to OEMs in medical diagnostic imaging, non-destructive inspection, security and cargo inspection as well as analysis. Headquartered in Salt Lake City, Utah, it was spun out of Varian Medical Systems in 2017 and employs approximately 2,400 people across North America, Europe and Asia.

Third quarter FY2026 results, released ten minutes after the announcement, showed revenue of $210.5MM, up 4% year over year, with Medical at $134.0MM and Industrial at $76.5MM. GAAP diluted EPS was $0.37, and non-GAAP EPS was $0.31 against $0.13 a year earlier. Non-GAAP operating margin was 12%, and adjusted EBITDA was $33.1MM versus $27.5MM. The quarter included $17MM of tariff refunds and a $7MM revenue reduction for expected customer reimbursements, so the underlying run rate is probably better read across a longer period. For FY2025, ended October 3, 2025, revenue was $845MM with adjusted EBITDA of $121.9MM and a non-GAAP operating margin of 9%, so operating leverage may already be improving.

Broader Implications for Precision Instrumentation M&A

The transaction sits within an active year for medtech and precision instrumentation consolidation. Reported 2026 transactions include Boston Scientific’s approximately $14.5Bn acquisition of Penumbra in January, Danaher’s approximately $9.9Bn acquisition of Masimo, which closed in June, KKR’s approximately $5.7Bn acquisition of Integer Holdings in August and the approximately $1.5Bn acquisition of Teleflex Medical OEM by Kohlberg and Montagu in August. Varex appears to be the year’s marquee imaging-components transaction and one of the few strategic-industrial acquisitions of a healthcare-exposed supplier.

Suppliers with entrenched OEM positions appear to be attracting acquirers that value technology depth over end-market brand. Diversified industrials also appear willing to underwrite healthcare exposure when the asset sits upstream of the regulated device. Photon-counting CT adoption is probably the underlying pull, since it likely raises the value of detector intellectual property relative to system assembly. Industry estimates suggest an X-ray detector market of roughly $4.4Bn in 2026, which would make component-level scale a defensible position rather than a niche one. A premium of approximately 52% to an unaffected close suggests acquirers may be prepared to pay for scarcity in hard-to-reproduce technology.

Conclusion

The transaction appears to continue an approach Teledyne has followed for more than a decade: acquiring technically differentiated assets adjacent to existing capabilities. The gap between Varex’s approximately 12% non-GAAP operating margin and the roughly 23% posted by Teledyne’s Digital Imaging segment is likely the central financial thesis, although neither party quantified any expected improvement. Closing remains subject to stockholder approval, U.S. antitrust clearance and foreign merger control clearances, so the timetable may extend if a single jurisdiction moves slowly. The lesson likely concerns positioning rather than price, since assets upstream of the finished system appear to be drawing strategic attention in the current cycle. Owners of similarly positioned businesses may wish to consider how their technology and manufacturing depth would be assessed by an industrial acquirer rather than a financial one.

About DelMorgan & Co. (www.delmorganco.com)

With over $300 billion of successful transactions in over 80 countries, DelMorgan’s Investment Banking professionals have worked on some of the most challenging, most rewarding and highest profile transactions in the U.S. and around the globe. DelMorgan specializes in capital raising and M&A advisor services for companies across all industries and is recognized as one of the leading investment banking practices in California and globally.

Learn more about DelMorgan’s Capabilities, Transactions, and why DelMorgan is ranked as the #1 Investment Bank in Los Angeles and #2 in California by Axial.